Shares of Recro Pharma Inc (NASDAQ:REPH) were up 5.6% on Wednesday . The company traded as high as $11.60 and last traded at $10.96. Approximately 630,974 shares were traded during mid-day trading, an increase of 206% from the average daily volume of 206,403 shares. The stock had previously closed at $10.38.
A number of analysts have weighed in on REPH shares. Oppenheimer set a $19.00 price target on Recro Pharma and gave the stock a “buy” rating in a research report on Wednesday, February 28th. Zacks Investment Research raised Recro Pharma from a “hold” rating to a “buy” rating and set a $9.75 price objective for the company in a research report on Wednesday, November 15th. ValuEngine raised Recro Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. CIBC began coverage on Recro Pharma in a research report on Wednesday, February 14th. They set an “outperform” rating and a $19.00 price objective for the company. Finally, UBS Group began coverage on Recro Pharma in a research report on Tuesday, February 13th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $13.75.
The company has a debt-to-equity ratio of 1.86, a current ratio of 1.75 and a quick ratio of 1.55. The firm has a market cap of $194.82, a PE ratio of -4.14 and a beta of -0.59.
A number of institutional investors have recently bought and sold shares of REPH. Teachers Advisors LLC acquired a new position in Recro Pharma in the 2nd quarter valued at approximately $162,000. TIAA CREF Investment Management LLC acquired a new position in Recro Pharma in the 2nd quarter valued at approximately $249,000. Northern Trust Corp raised its holdings in Recro Pharma by 428.5% in the 2nd quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock valued at $1,254,000 after acquiring an additional 144,676 shares in the last quarter. Vanguard Group Inc. raised its holdings in Recro Pharma by 14.2% in the 2nd quarter. Vanguard Group Inc. now owns 640,208 shares of the specialty pharmaceutical company’s stock valued at $4,501,000 after acquiring an additional 79,520 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Recro Pharma by 787.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 129,560 shares of the specialty pharmaceutical company’s stock valued at $911,000 after acquiring an additional 114,960 shares in the last quarter. 59.23% of the stock is owned by hedge funds and other institutional investors.
WARNING: “Recro Pharma (REPH) Trading Up 5.6%” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://sportsperspectives.com/2018/03/14/recro-pharma-reph-trading-up-5-6.html.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.